Central venous access device-associated contact dermatitis in patients with cancer: The utility of extensive screening patch tests

Contact Dermatitis. 2021 May;84(5):348-350. doi: 10.1111/cod.13744. Epub 2020 Dec 7.

Authors

Pierre Marcant^{1

2}, Alexandra Moreau¹, Aline Da Silva³, Capucine Aelbrecht-Meurisse⁴, Delphine Staumont-Sallé^{1

2}

Affiliations

¹ CHU de Lille, Service de dermatologie, Lille, France.
² University of Lille, Lille, France.
³ CH de Valenciennes, Service d'oncologie, Valenciennes, France.
⁴ Centre Oscar Lambret, Service d'oncologie, Lille, France.

PMID: 33210314
DOI: 10.1111/cod.13744

No abstract available

Keywords: Dermabond; case report; central venous access devices; contact dermatitis; disinfectants.

Publication types

Case Reports

MeSH terms

Adult
Anti-Infective Agents, Local / adverse effects*
Antineoplastic Agents / administration & dosage
Central Venous Catheters / adverse effects*
Cyanoacrylates / adverse effects*
Dermatitis, Allergic Contact / etiology*
Dermatitis, Irritant / etiology*
Humans
Male
Povidone-Iodine / adverse effects
Testicular Neoplasms / drug therapy
Testicular Neoplasms / secondary
Tissue Adhesives / adverse effects*

Substances

Anti-Infective Agents, Local
Antineoplastic Agents
Cyanoacrylates
Tissue Adhesives
octyl 2-cyanoacrylate
Povidone-Iodine